Pain Management Drugs Market
完整報告名稱與涵蓋範圍
Pain Management Drugs Market Size, Share & Trends Analysis Report, By Drug Class (NSAIDs, Opioids, Anticonvulsants, Antidepressants, Local Anesthetics, Non-Opioid Novel Analgesics), By Indication (Chronic Back Pain, Arthritic Pain, Neuropathic Pain, Cancer Pain, Post-Operative Pain, Migraine & Headache), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
Pain management drugs comprise prescription and over-the-counter pharmacotherapies for acute and chronic pain, covering NSAIDs, opioid analgesics, anticonvulsants and antidepressants used for neuropathic conditions, local anesthetics including long-acting surgical formulations, and an emerging class of non-opioid novel analgesics such as selective sodium channel blockers. The scope spans chronic back and arthritic pain, neuropathy, cancer pain, post-operative analgesia and migraine, across hospital, retail and online dispensing.
The market's defining dynamic is substitution away from opioids. Prescribing restrictions, abuse-deterrent requirements and litigation-driven caution have compressed traditional opioid volumes in North America, redirecting demand toward anticonvulsant and antidepressant regimens for neuropathic pain, long-acting local anesthetic techniques for surgical recovery, and the first approved selective NaV1.8 inhibitors, whose arrival validates a new mechanism after decades without one. Underlying need continues to expand with ageing populations carrying osteoarthritis and degenerative spine disease, rising surgical volumes requiring multimodal analgesia protocols, and greater diagnosis of diabetic peripheral neuropathy. Payers increasingly reward non-addictive options, while genericisation of established analgesics keeps price pressure high in mature classes.
North America remains the largest market by value given premium pricing of branded non-opioid entrants, Europe emphasises generic multimodal regimens under cost containment, and Asia Pacific delivers volume growth as surgical capacity and chronic disease diagnosis widen in China and India. Competition splits between global originators advancing novel mechanisms, generics manufacturers dominating volume, and consumer health players in the OTC analgesic tier.
The InsightAce study provides US$ revenue forecasts across all drug class, indication, distribution channel and regional segments for 2026-2035, with segment-level trends, competitive landscape analysis and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Pain Management Drugs Market Snapshot
Chapter 4. Global Pain Management Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. Drug Class & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Class:
5.2.1. NSAIDs
5.2.2. Opioids
5.2.3. Anticonvulsants
5.2.4. Antidepressants
5.2.5. Local Anesthetics
5.2.6. Non-Opioid Novel Analgesics
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Chronic Back Pain
6.2.2. Arthritic Pain
6.2.3. Neuropathic Pain
6.2.4. Cancer Pain
6.2.5. Post-Operative Pain
6.2.6. Migraine & Headache
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. Distribution Channel & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Pain Management Drugs Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Pfizer Inc.
10.2. Eli Lilly and Company
10.3. Vertex Pharmaceuticals
10.4. Grunenthal GmbH
10.5. Teva Pharmaceutical Industries
10.6. Viatris Inc.
10.7. Bayer AG
10.8. Haleon plc
10.9. Sun Pharmaceutical Industries
10.10. Hikma Pharmaceuticals
10.11. Collegium Pharmaceutical
10.12. Pacira BioSciences
10.13. Endo Inc.
10.14. AbbVie Inc.
圖表清單 List of Tables & Figures
Table 1. Global Pain Management Drugs Revenue Forecast by Drug Class, 2026-2035 (US$ Mn)
Figure 1. Pain Pharmacotherapy Landscape by Mechanism of Action
Table 2. Global Pain Management Drugs Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Pain Management Drugs Share by Drug Class, 2026 & 2035
Table 3. Global Pain Management Drugs Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 3. Opioid Prescribing Trends and Non-Opioid Substitution Pathways
Table 4. North America Pain Management Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Pipeline of Non-Opioid Novel Analgesics by Mechanism and Phase
Table 5. Europe Pain Management Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Pain Management Drugs Growth Opportunity Analysis
Table 6. Asia Pacific Pain Management Drugs Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Multimodal Post-Operative Analgesia Protocol Adoption Trends
Table 7. Genericisation Timeline of Major Analgesic Brands
Figure 7. Competitive Positioning of Key Pain Management Drug Companies
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們